{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T11:05:22Z","timestamp":1789038322138,"version":"build-2803163510"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"publisher","award":["WE.03-2018-05"],"award-info":[{"award-number":["WE.03-2018-05"]}],"id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"publisher","award":["WE.03-2018-05"],"award-info":[{"award-number":["WE.03-2018-05"]}],"id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022692","name":"Selfridges Group Foundation","doi-asserted-by":"publisher","award":["NR170065"],"award-info":[{"award-number":["NR170065"]}],"id":[{"id":"10.13039\/501100022692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022692","name":"Selfridges Group Foundation","doi-asserted-by":"publisher","award":["NR170065"],"award-info":[{"award-number":["NR170065"]}],"id":[{"id":"10.13039\/501100022692","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fondo de Investigaciones Sanitario","award":["PI21\/00791, PI14\/01126, PI17\/01019, PI20\/01473, PI13\/01532, PI16\/01825, PI18\/00335, PI19\/00882, PI18\/00435, PI22\/00611, INT19\/00016, INT23\/00048, PI17\/01896 and AC19\/00103"],"award-info":[{"award-number":["PI21\/00791, PI14\/01126, PI17\/01019, PI20\/01473, PI13\/01532, PI16\/01825, PI18\/00335, PI19\/00882, PI18\/00435, PI22\/00611, INT19\/00016, INT23\/00048, PI17\/01896 and AC19\/00103"]}]},{"name":"Fondo de Investigaciones Sanitario","award":["PI21\/00791, PI14\/01126, PI17\/01019, PI20\/01473, PI13\/01532, PI16\/01825, PI18\/00335, PI19\/00882, PI18\/00435, PI22\/00611, INT19\/00016, INT23\/00048, PI17\/01896 and AC19\/00103"],"award-info":[{"award-number":["PI21\/00791, PI14\/01126, PI17\/01019, PI20\/01473, PI13\/01532, PI16\/01825, PI18\/00335, PI19\/00882, PI18\/00435, PI22\/00611, INT19\/00016, INT23\/00048, PI17\/01896 and AC19\/00103"]}]},{"name":"CIBERNED program","award":["Program 1, Alzheimer Disease"],"award-info":[{"award-number":["Program 1, Alzheimer Disease"]}]},{"name":"CIBERNED program","award":["Program 1, Alzheimer Disease"],"award-info":[{"award-number":["Program 1, Alzheimer Disease"]}]},{"name":"Fondo Europeo de Desarrollo Regional, Unio\u0301n Europea, \u201cUna manera de hacer Europa"},{"DOI":"10.13039\/100000063","name":"Office of Dietary Supplements","doi-asserted-by":"publisher","award":["NIA grants 1R01AG056850-01A1; R21AG056974; and R01AG061566),"],"award-info":[{"award-number":["NIA grants 1R01AG056850-01A1; R21AG056974; and R01AG061566),"]}],"id":[{"id":"10.13039\/100000063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000063","name":"Office of Dietary Supplements","doi-asserted-by":"publisher","award":["NIA grants 1R01AG056850-01A1; R21AG056974; and R01AG061566),"],"award-info":[{"award-number":["NIA grants 1R01AG056850-01A1; R21AG056974; and R01AG061566),"]}],"id":[{"id":"10.13039\/100000063","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2017-SGR-547, SLT006\/17\/125, SLT006\/17\/119, SLT002\/16\/408"],"award-info":[{"award-number":["2017-SGR-547, SLT006\/17\/125, SLT006\/17\/119, SLT002\/16\/408"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2017-SGR-547, SLT006\/17\/125, SLT006\/17\/119, SLT002\/16\/408"],"award-info":[{"award-number":["2017-SGR-547, SLT006\/17\/125, SLT006\/17\/119, SLT002\/16\/408"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["20141210, 044412 and 20142610"],"award-info":[{"award-number":["20141210, 044412 and 20142610"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["20141210, 044412 and 20142610"],"award-info":[{"award-number":["20141210, 044412 and 20142610"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fundaci\u00f3 Bancaria La Caixa"},{"name":"Fundaci\u00f3 Catalana S\u00edndrome de Down"},{"DOI":"10.13039\/501100014376","name":"Fundaci\u00f3 V\u00edctor Gr\u00edfols i Lucas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014376","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01799-3","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T17:49:14Z","timestamp":1753206554000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CHIT1 and DDAH1 levels relate to amyloid-related imaging abnormalities risk profile in Alzheimer\u2019s disease patients"],"prefix":"10.1186","volume":"17","author":[{"given":"Marlies","family":"Oosthoek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everard G.B.","family":"Vijverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena R.","family":"Blujdea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjors G.J.G. In\u2019t","family":"Veld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn Pucheu","family":"Avil\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ra E.","family":"Zsadanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanaika S.","family":"Hok-A-Hin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allerdien","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Barkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"del Campo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn C.","family":"Schut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bejanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Vermunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"1799_CR1","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384:1691\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2100708.","journal-title":"N Engl J Med"},{"key":"1799_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.3392","author":"MJ Pontecorvo","year":"2022","unstructured":"Pontecorvo MJ, et al. Association of Donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease: A secondary analysis of the TRAILBLAZER-ALZ randomized clinical trial. JAMA Neurol. 2022. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3392.","journal-title":"JAMA Neurol"},{"key":"1799_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948","author":"CH van Dyck","year":"2022","unstructured":"van Dyck CH, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"key":"1799_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimer\u2019s Disease. 2022;9:197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30.","journal-title":"J Prev Alzheimer\u2019s Disease"},{"key":"1799_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s association research roundtable workgroup. Alzheimer\u2019s Dement. 2011;7:367\u201385. https:\/\/doi.org\/10.1016\/j.jalz.2011.05.2351.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1799_CR6","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3174\/ajnr.A3500","volume":"34","author":"J Barakos","year":"2013","unstructured":"Barakos J, et al. MR imaging features of Amyloid-Related imaging abnormalities. Am J Neuroradiol. 2013;34:1958. https:\/\/doi.org\/10.3174\/ajnr.A3500.","journal-title":"Am J Neuroradiol"},{"key":"1799_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512\u201327. https:\/\/doi.org\/10.1001\/jama.2023.13239.","journal-title":"JAMA"},{"key":"1799_CR8","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","volume":"13","author":"CJ Swanson","year":"2021","unstructured":"Swanson CJ, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer\u2019s disease with lecanemab, an anti-A\u03b2 protofibril antibody. Alzheimers Res Ther. 2021;13:80. https:\/\/doi.org\/10.1186\/s13195-021-00813-8.","journal-title":"Alzheimers Res Ther"},{"key":"1799_CR9","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","volume":"73","author":"S Salloway","year":"2009","unstructured":"Salloway S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73:2061. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c67808.","journal-title":"Neurology"},{"key":"1799_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMc2215148","volume":"388","author":"NJ Reish","year":"2023","unstructured":"Reish NJ, et al. Multiple cerebral hemorrhages in a patient receiving Lecanemab and treated with t-PA for stroke. N Engl J Med. 2023;388:478\u20139.","journal-title":"N Engl J Med"},{"key":"1799_CR11","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3233\/JAD-221305","volume":"93","author":"RJ Castellani","year":"2023","unstructured":"Castellani RJ, et al. Neuropathology of Anti-Amyloid-\u03b2 immunotherapy: A case report. J Alzheimers Dis. 2023;93:803\u201313. https:\/\/doi.org\/10.3233\/JAD-221305.","journal-title":"J Alzheimers Dis"},{"key":"1799_CR12","doi-asserted-by":"publisher","first-page":"8220","DOI":"10.1038\/s41467-023-43933-5","volume":"14","author":"E Solopova","year":"2023","unstructured":"Solopova E, et al. Fatal iatrogenic cerebral \u03b2-amyloid-related arteritis in a woman treated with Lecanemab for Alzheimer\u2019s disease. Nat Commun. 2023;14:8220. https:\/\/doi.org\/10.1038\/s41467-023-43933-5.","journal-title":"Nat Commun"},{"key":"1799_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13024-023-00649-w","volume":"18","author":"X Taylor","year":"2023","unstructured":"Taylor X, et al. Amyloid-\u03b2 (A\u03b2) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer\u2019s disease mice. Mol Neurodegeneration. 2023;18:59. https:\/\/doi.org\/10.1186\/s13024-023-00649-w.","journal-title":"Mol Neurodegeneration"},{"key":"1799_CR14","unstructured":"Alzforum L. Side Effects No Worse in Clinical Use Than They Were in Trial, <https:\/\/www.alzforum.org\/news\/conference-coverage\/leqembi-side-effects-no-worse-clinical-use-they-were-trial (2024)."},{"key":"1799_CR15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ana.26511","volume":"92","author":"N Joseph-Mathurin","year":"2022","unstructured":"Joseph-Mathurin N, et al. Amyloid-Related imaging abnormalities in the DIAN-TU-001 trial of gantenerumab and solanezumab: lessons from a trial in dominantly inherited Alzheimer disease. Ann Neurol. 2022;92:729\u201344. https:\/\/doi.org\/10.1002\/ana.26511.","journal-title":"Ann Neurol"},{"key":"1799_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.14283\/jpad.2022.21","volume":"9","author":"J Barakos","year":"2022","unstructured":"Barakos J, et al. Detection and management of Amyloid-Related imaging abnormalities in patients with Alzheimer\u2019s disease treated with Anti-Amyloid Beta therapy. J Prev Alzheimers Dis. 2022;9:211\u201320. https:\/\/doi.org\/10.14283\/jpad.2022.21.","journal-title":"J Prev Alzheimers Dis"},{"key":"1799_CR17","doi-asserted-by":"publisher","unstructured":"Jeong SY et al. Incidence of Amyloid-Related Imaging Abnormalities in Patients With Alzheimer Disease Treated With Anti-\u03b2-Amyloid Immunotherapy: A Meta-analysis. Neurology. 2022;99:e2092-e2101. https:\/\/doi.org\/10.1212\/wnl.0000000000201019","DOI":"10.1212\/wnl.0000000000201019"},{"key":"1799_CR18","doi-asserted-by":"publisher","first-page":"1326784","DOI":"10.3389\/fnins.2024.1326784","volume":"18","author":"SJ Doran","year":"2024","unstructured":"Doran SJ, Sawyer RP. Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. Front Neurosci. 2024;18:1326784. https:\/\/doi.org\/10.3389\/fnins.2024.1326784.","journal-title":"Front Neurosci"},{"key":"1799_CR19","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1002\/ana.26610","volume":"93","author":"AM De Kort","year":"2023","unstructured":"De Kort AM, et al. Decreased cerebrospinal fluid amyloid \u03b2 38, 40, 42, and 43 levels in sporadic and hereditary cerebral amyloid angiopathy. Ann Neurol. 2023;93:1173\u201386. https:\/\/doi.org\/10.1002\/ana.26610.","journal-title":"Ann Neurol"},{"key":"1799_CR20","doi-asserted-by":"publisher","first-page":"2445194","DOI":"10.1080\/07853890.2024.2445194","volume":"57","author":"H Hu","year":"2025","unstructured":"Hu H, et al. Deciphering the role of APOE in cerebral amyloid angiopathy: from genetic insights to therapeutic horizons. Ann Med. 2025;57:2445194. https:\/\/doi.org\/10.1080\/07853890.2024.2445194.","journal-title":"Ann Med"},{"key":"1799_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13195-018-0359-x","volume":"10","author":"CE Teunissen","year":"2018","unstructured":"Teunissen CE, et al. White paper by the society for CSF analysis and clinical neurochemistry: overcoming barriers in biomarker development and clinical translation. Alzheimers Res Ther. 2018;10:30. https:\/\/doi.org\/10.1186\/s13195-018-0359-x.","journal-title":"Alzheimers Res Ther"},{"key":"1799_CR22","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/s43587-022-00300-1","volume":"2","author":"M del Campo","year":"2022","unstructured":"del Campo M, et al. CSF proteome profiling across the Alzheimer\u2019s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels. Nat Aging. 2022;2:1040\u201353. https:\/\/doi.org\/10.1038\/s43587-022-00300-1.","journal-title":"Nat Aging"},{"key":"1799_CR23","doi-asserted-by":"publisher","unstructured":"Hok-A-Hin YS et al. Large-scale CSF proteome profiling identifies biomarkers for accurate diagnosis of frontotemporal dementia. MedRxiv, 2024.2008.2019.24312100 (2024). https:\/\/doi.org\/10.1101\/2024.08.19.24312100","DOI":"10.1101\/2024.08.19.24312100"},{"key":"1799_CR24","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1038\/s41467-023-41122-y","volume":"14","author":"M del Campo","year":"2023","unstructured":"del Campo M, et al. CSF proteome profiling reveals biomarkers to discriminate dementia with lewy bodies from Alzheimer\u00b4s disease. Nat Commun. 2023;14:5635. https:\/\/doi.org\/10.1038\/s41467-023-41122-y.","journal-title":"Nat Commun"},{"key":"1799_CR25","doi-asserted-by":"publisher","first-page":"e12456","DOI":"10.1002\/dad2.12456","volume":"15","author":"AHYS Hok","year":"2023","unstructured":"Hok AHYS, et al. Thimet oligopeptidase as a potential CSF biomarker for Alzheimer\u2019s disease: A cross-platform validation study. Alzheimers Dement (Amst). 2023;15:e12456. https:\/\/doi.org\/10.1002\/dad2.12456.","journal-title":"Alzheimers Dement (Amst)"},{"key":"1799_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3233\/jad-132306","volume":"41","author":"WM van der Flier","year":"2014","unstructured":"van der Flier WM, et al. Optimizing patient care and research: the Amsterdam dementia cohort. J Alzheimers Dis. 2014;41:313\u201327. https:\/\/doi.org\/10.3233\/jad-132306.","journal-title":"J Alzheimers Dis"},{"key":"1799_CR27","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM van der Flier","year":"2018","unstructured":"van der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis. 2018;62:1091\u2013111. https:\/\/doi.org\/10.3233\/JAD-170850.","journal-title":"J Alzheimers Dis"},{"key":"1799_CR28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.trci.2019.09.005","volume":"5","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, et al. The Sant Pau initiative on neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimers Dement (N Y). 2019;5:597\u2013609. https:\/\/doi.org\/10.1016\/j.trci.2019.09.005.","journal-title":"Alzheimers Dement (N Y)"},{"key":"1799_CR29","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/s1474-4422(07)70178-3","volume":"6","author":"B Dubois","year":"2007","unstructured":"Dubois B, et al. Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6:734\u201346. https:\/\/doi.org\/10.1016\/s1474-4422(07)70178-3.","journal-title":"Lancet Neurol"},{"key":"1799_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.005.","journal-title":"Alzheimers Dement"},{"key":"1799_CR31","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1373\/clinchem.2017.281055","volume":"64","author":"BM Tijms","year":"2018","unstructured":"Tijms BM, et al. Unbiased approach to counteract upward drift in cerebrospinal fluid Amyloid-\u03b2 1\u201342 analysis results. Clin Chem. 2018;64:576\u201385. https:\/\/doi.org\/10.1373\/clinchem.2017.281055.","journal-title":"Clin Chem"},{"key":"1799_CR32","doi-asserted-by":"publisher","unstructured":"Duits FH et al. The cerebrospinal fluid Alzheimer profile: Easily said, but what does it mean? Alzheimer\u2019s & Dementia 10, 713\u2013e723712 (2014). https:\/\/doi.org\/10.1016\/j.jalz.2013.12.023","DOI":"10.1016\/j.jalz.2013.12.023"},{"key":"1799_CR33","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/acn3.50873","volume":"6","author":"D Alcolea","year":"2019","unstructured":"Alcolea D, et al. Agreement of amyloid PET and CSF biomarkers for Alzheimer\u2019s disease on lumipulse. Ann Clin Transl Neurol. 2019;6:1815\u201324. https:\/\/doi.org\/10.1002\/acn3.50873.","journal-title":"Ann Clin Transl Neurol"},{"key":"1799_CR34","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1212\/WNL.0b013e3181e396ea","volume":"74","author":"JD Goos","year":"2010","unstructured":"Goos JD, et al. Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurology. 2010;74:1954\u201360. https:\/\/doi.org\/10.1212\/WNL.0b013e3181e396ea.","journal-title":"Neurology"},{"key":"1799_CR35","doi-asserted-by":"publisher","first-page":"e1632","DOI":"10.1212\/wnl.0000000000011542","volume":"96","author":"N Joseph-Mathurin","year":"2021","unstructured":"Joseph-Mathurin N, et al. Longitudinal accumulation of cerebral microhemorrhages in dominantly inherited Alzheimer disease. Neurology. 2021;96:e1632\u201345. https:\/\/doi.org\/10.1212\/wnl.0000000000011542.","journal-title":"Neurology"},{"key":"1799_CR36","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","volume":"82","author":"JA Zimmer","year":"2025","unstructured":"Zimmer JA, et al. Amyloid-Related imaging abnormalities with Donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials. JAMA Neurol. 2025;82:461\u20139. https:\/\/doi.org\/10.1001\/jamaneurol.2025.0065.","journal-title":"JAMA Neurol"},{"key":"1799_CR37","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis. 2023;10:362\u201377. https:\/\/doi.org\/10.14283\/jpad.2023.30.","journal-title":"J Prev Alzheimers Dis"},{"key":"1799_CR38","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1212\/01.wnl.0000210535.20297.ae","volume":"66","author":"C Cordonnier","year":"2006","unstructured":"Cordonnier C, et al. Prevalence and severity of microbleeds in a memory clinic setting. Neurology. 2006;66:1356\u201360. https:\/\/doi.org\/10.1212\/01.wnl.0000210535.20297.ae.","journal-title":"Neurology"},{"key":"1799_CR39","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman R. A. MR signal abnormalities at 1.5 T in Alzheimer\u2019s dementia and normal aging. AJR Am J Roentgenol. 1987;149:351\u20136. https:\/\/doi.org\/10.2214\/ajr.149.2.351.","journal-title":"AJR Am J Roentgenol"},{"key":"1799_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-1-4939-9706-0_2","volume":"2044","author":"AHYS Hok","year":"2019","unstructured":"Hok AHYS, Willemse EAJ, Teunissen CE, Del Campo M. Guidelines for CSF processing and biobanking: impact on the identification and development of optimal CSF protein biomarkers. Methods Mol Biol. 2019;2044:27\u201350. https:\/\/doi.org\/10.1007\/978-1-4939-9706-0_2.","journal-title":"Methods Mol Biol"},{"key":"1799_CR41","unstructured":"Proteomics O. Development and validation of customized PEA biomarker panels with clinical utility. (2021)."},{"key":"1799_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i03","volume":"45","author":"S van Buuren","year":"2011","unstructured":"van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45:1\u201367. https:\/\/doi.org\/10.18637\/jss.v045.i03.","journal-title":"J Stat Softw"},{"key":"1799_CR43","doi-asserted-by":"publisher","first-page":"100141","DOI":"10.1016\/j.xinn.2021.100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, et al. ClusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov (Camb). 2021;2:100141. https:\/\/doi.org\/10.1016\/j.xinn.2021.100141.","journal-title":"Innov (Camb)"},{"key":"1799_CR44","first-page":"69","volume":"24","author":"MM Mukaka","year":"2012","unstructured":"Mukaka MM. Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J. 2012;24:69\u201371.","journal-title":"Malawi Med J"},{"key":"1799_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.semcdb.2022.03.013","volume":"139","author":"B Zott","year":"2023","unstructured":"Zott B, Konnerth A. Impairments of glutamatergic synaptic transmission in Alzheimer\u2019s disease. Semin Cell Dev Biol. 2023;139:24\u201334. https:\/\/doi.org\/10.1016\/j.semcdb.2022.03.013.","journal-title":"Semin Cell Dev Biol"},{"key":"1799_CR46","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nn.3901","volume":"18","author":"C Murphy-Royal","year":"2015","unstructured":"Murphy-Royal C, et al. Surface diffusion of astrocytic glutamate transporters shapes synaptic transmission. Nat Neurosci. 2015;18:219\u201326. https:\/\/doi.org\/10.1038\/nn.3901.","journal-title":"Nat Neurosci"},{"key":"1799_CR47","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1038\/s42003-024-06540-8","volume":"7","author":"L Squadrani","year":"2024","unstructured":"Squadrani L, et al. Astrocytes enhance plasticity response during reversal learning. Commun Biology. 2024;7:852. https:\/\/doi.org\/10.1038\/s42003-024-06540-8.","journal-title":"Commun Biology"},{"key":"1799_CR48","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n M, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419. https:\/\/doi.org\/10.1126\/science.1260419.","journal-title":"Science"},{"key":"1799_CR49","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/nbt1210-1248","volume":"28","author":"M Uhlen","year":"2010","unstructured":"Uhlen M, et al. Towards a knowledge-based human protein atlas. Nat Biotechnol. 2010;28:1248\u201350. https:\/\/doi.org\/10.1038\/nbt1210-1248.","journal-title":"Nat Biotechnol"},{"key":"1799_CR50","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13024-024-00758-0","volume":"19","author":"X Taylor","year":"2024","unstructured":"Taylor X, et al. Amyloid-\u03b2 (A\u03b2) immunotherapy induced microhemorrhages are linked to vascular inflammation and cerebrovascular damage in a mouse model of Alzheimer\u2019s disease. Mol Neurodegeneration. 2024;19:77. https:\/\/doi.org\/10.1186\/s13024-024-00758-0.","journal-title":"Mol Neurodegeneration"},{"key":"1799_CR51","doi-asserted-by":"publisher","first-page":"102075","DOI":"10.1016\/j.pneurobio.2021.102075","volume":"203","author":"S Chung","year":"2021","unstructured":"Chung S, et al. Plexin-A4 mediates amyloid-\u03b2\u2013induced Tau pathology in Alzheimer\u2019s disease animal model. Prog Neurobiol. 2021;203:102075. https:\/\/doi.org\/10.1016\/j.pneurobio.2021.102075.","journal-title":"Prog Neurobiol"},{"key":"1799_CR52","doi-asserted-by":"publisher","first-page":"105999","DOI":"10.1016\/j.neubiorev.2024.105999","volume":"169","author":"A Khan","year":"2025","unstructured":"Khan A, Sharma P, Dahiya S, Sharma B, Plexins. Navigating through the neural regulation and brain pathology. Neurosci Biobehavioral Reviews. 2025;169:105999. https:\/\/doi.org\/10.1016\/j.neubiorev.2024.105999.","journal-title":"Neurosci Biobehavioral Reviews"},{"key":"1799_CR53","doi-asserted-by":"publisher","first-page":"H3227","DOI":"10.1152\/ajpheart.00998.2007","volume":"293","author":"F Palm","year":"2007","unstructured":"Palm F, Onozato ML, Luo Z, Wilcox CS. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol. 2007;293:H3227\u20133245. https:\/\/doi.org\/10.1152\/ajpheart.00998.2007.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1799_CR54","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1016\/j.apsb.2024.02.001","volume":"14","author":"Q Gao","year":"2024","unstructured":"Gao Q, et al. DDAH1 promotes neurogenesis and neural repair in cerebral ischemia. Acta Pharm Sinica B. 2024;14:2097\u2013118. https:\/\/doi.org\/10.1016\/j.apsb.2024.02.001. https:\/\/doi.org\/https:\/\/doi.org\/.","journal-title":"Acta Pharm Sinica B"},{"key":"1799_CR55","doi-asserted-by":"publisher","first-page":"2303259","DOI":"10.1002\/advs.202303259","volume":"10","author":"SM Andrabi","year":"2023","unstructured":"Andrabi SM, et al. Nitric oxide: physiological functions, delivery, and biomedical applications. Adv Sci. 2023;10:2303259. https:\/\/doi.org\/10.1002\/advs.202303259.","journal-title":"Adv Sci"},{"key":"1799_CR56","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/s41374-021-00541-5","volume":"101","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, et al. DDAH-1, via regulation of ADMA levels, protects against ischemia-induced blood-brain barrier leakage. Lab Invest. 2021;101:808\u201323. https:\/\/doi.org\/10.1038\/s41374-021-00541-5.","journal-title":"Lab Invest"},{"key":"1799_CR57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.niox.2019.12.004","volume":"95","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, et al. DDAH-1 via HIF-1 target genes improves cerebral ischemic tolerance after hypoxic preconditioning and middle cerebral artery occlusion-reperfusion. Nitric Oxide. 2020;95:17\u201328. https:\/\/doi.org\/10.1016\/j.niox.2019.12.004.","journal-title":"Nitric Oxide"},{"key":"1799_CR58","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1179\/016164111x13007856084403","volume":"33","author":"N Li","year":"2011","unstructured":"Li N, Worthmann H, Deb M, Chen S, Weissenborn K. Nitric oxide (NO) and asymmetric dimethylarginine (ADMA): their pathophysiological role and involvement in intracerebral hemorrhage. Neurol Res. 2011;33:541\u20138. https:\/\/doi.org\/10.1179\/016164111x13007856084403.","journal-title":"Neurol Res"},{"key":"1799_CR59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s43587-023-00550-7","volume":"4","author":"BM Tijms","year":"2024","unstructured":"Tijms BM, et al. Cerebrospinal fluid proteomics in patients with Alzheimer\u2019s disease reveals five molecular subtypes with distinct genetic risk profiles. Nat Aging. 2024;4:33\u201347. https:\/\/doi.org\/10.1038\/s43587-023-00550-7.","journal-title":"Nat Aging"},{"key":"1799_CR60","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-019-0562-4","volume":"12","author":"S Abu-Rumeileh","year":"2019","unstructured":"Abu-Rumeileh S, et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimers Res Ther. 2019;12:2. https:\/\/doi.org\/10.1186\/s13195-019-0562-4.","journal-title":"Alzheimers Res Ther"},{"key":"1799_CR61","doi-asserted-by":"publisher","unstructured":"Sklepkiewicz P, et al. Inhibition of Macrophage-Specific CHIT1 as an approach to treat airway remodeling in severe asthma. Int J Mol Sci. 2023;24. https:\/\/doi.org\/10.3390\/ijms24054719.","DOI":"10.3390\/ijms24054719"},{"key":"1799_CR62","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ijbiomac.2017.01.042","volume":"97","author":"S Patel","year":"2017","unstructured":"Patel S, Goyal A. Chitin and chitinase: role in pathogenicity, allergenicity and health. Int J Biol Macromol. 2017;97:331\u20138. https:\/\/doi.org\/10.1016\/j.ijbiomac.2017.01.042. https:\/\/doi.org\/https:\/\/doi.org\/.","journal-title":"Int J Biol Macromol"},{"key":"1799_CR63","doi-asserted-by":"publisher","unstructured":"Pinteac R, Montalban X, Comabella M. Chitinases and chitinase-like proteins as biomarkers in neurologic disorders. Neurol Neuroimmunol Neuroinflamm. 2021;8. https:\/\/doi.org\/10.1212\/nxi.0000000000000921.","DOI":"10.1212\/nxi.0000000000000921"},{"key":"1799_CR64","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/path.6387","volume":"265","author":"S Yuan","year":"2025","unstructured":"Yuan S, et al. CHIT1 regulates the neuroinflammation and phagocytosis of microglia and suppresses A\u03b2 plaque deposition in Alzheimer\u2019s disease. J Pathol. 2025;265:330\u201341. https:\/\/doi.org\/10.1002\/path.6387.","journal-title":"J Pathol"},{"key":"1799_CR65","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1093\/brain\/awad213","volume":"146","author":"EL van der Ende","year":"2023","unstructured":"van der Ende EL, et al. CSF proteomics in autosomal dominant Alzheimer\u2019s disease highlights parallels with sporadic disease. Brain. 2023;146:4495\u2013507. https:\/\/doi.org\/10.1093\/brain\/awad213.","journal-title":"Brain"},{"key":"1799_CR66","doi-asserted-by":"publisher","first-page":"100629","DOI":"10.1016\/j.mcpro.2023.100629","volume":"22","author":"CE Teunissen","year":"2023","unstructured":"Teunissen CE, et al. Methods to discover and validate Biofluid-Based biomarkers in neurodegenerative dementias. Mol Cell Proteom. 2023;22:100629. https:\/\/doi.org\/10.1016\/j.mcpro.2023.100629.","journal-title":"Mol Cell Proteom"},{"key":"1799_CR67","doi-asserted-by":"publisher","first-page":"D130","DOI":"10.1093\/nar\/gkr1079","volume":"40","author":"KD Pruitt","year":"2012","unstructured":"Pruitt KD, Tatusova T, Brown GR, Maglott DR. NCBI reference sequences (RefSeq): current status, new features and genome annotation policy. Nucleic Acids Res. 2012;40:D130\u2013135. https:\/\/doi.org\/10.1093\/nar\/gkr1079.","journal-title":"Nucleic Acids Res"},{"key":"1799_CR68","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13195-022-01113-5","volume":"14","author":"EB Dammer","year":"2022","unstructured":"Dammer EB, et al. Multi-platform proteomic analysis of Alzheimer\u2019s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome. Alzheimers Res Ther. 2022;14:174. https:\/\/doi.org\/10.1186\/s13195-022-01113-5.","journal-title":"Alzheimers Res Ther"},{"key":"1799_CR69","doi-asserted-by":"publisher","unstructured":"Mavrina E, et al. Multi-Omics interdisciplinary research integration to accelerate dementia biomarker development (MIRIADE). Front Neurol. 2022;13. https:\/\/doi.org\/10.3389\/fneur.2022.890638.","DOI":"10.3389\/fneur.2022.890638"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01799-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01799-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01799-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T18:18:02Z","timestamp":1757269082000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-025-01799-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":69,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1799"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01799-3","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethical approval was given at the local review boards (Amsterdam Dementia Cohort: AD CSF biobank METC number 00\u2013211; SPIN cohort: COLLECTION 16\/2013). Written informed consent was provided by all study participants or a representative.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"169"}}